Literature DB >> 26853695

Association of coronary artery calcification with liver fibrosis in Japanese patients with non-alcoholic fatty liver disease.

Hiroshi Ishiba1, Yoshio Sumida2, Seita Kataoka3, Masaaki Kuroda3, Satoshi Akabame4, Kiichiro Tomiyasu4, Muhei Tanaka5, Masahiro Arai3, Hiroyoshi Taketani1, Yuya Seko1, Akira Okajima1, Tasuku Hara1, Atsushi Umemura1, Taichiro Nishikawa1, Kanji Yamaguchi1, Michihisa Moriguchi1, Hironori Mitsuyoshi1, Kohichiroh Yasui1, Yoshito Itoh1.   

Abstract

AIMS: Cardiovascular events are the leading cause of death among patients with non-alcoholic fatty liver disease (NAFLD), but their relationship remains unclear. This study examined the association between coronary atherosclerosis and liver fibrosis, represented by the coronary artery calcification (CAC) score and non-invasive fibrosis markers, respectively.
METHODS: Among 698 patients with chest pain or electrocardiographic abnormalities who underwent coronary computed tomography (CT) between April 2006 and March 2010, those with known liver disorders or history of emergency coronary angioplasty were excluded, leaving 366 patients for this study. Diagnosis of NAFLD was based on abdominal CT and history of alcohol consumption. Subjects with CAC of 100 AU or more were categorized into the high-risk group for cardiovascular events. Patient records were examined for clinical parameters including CAC score and non-invasive fibrosis marker FIB-4 index.
RESULTS: Ninety-four patients (25.7%) had NAFLD. In this group, univariate analysis identified old age, high diastolic blood pressure, high liver to spleen ratio and high FIB-4 index as risk factors for cardiovascular events and multivariate analysis identified age of 66 years or older and FIB-4 index of 2.09 or more as the significant risk factors. For the observation period until August 2014, the cumulative proportion of PCI performance was significantly higher in patients with FIB-4 of 2.09 or more than those with FIB-4 of less than 2.09.
CONCLUSION: The progression of arteriosclerosis and that of liver fibrosis may be associated in NAFLD patients. The FIB-4 index can be easily determined and thus can be a useful marker for predicting cardiovascular events in NAFLD patients.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  FIB-4 index; coronary artery calcification; coronary artery disease; liver fibrosis; non-alcoholic fatty liver disease

Year:  2016        PMID: 26853695     DOI: 10.1111/hepr.12665

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  8 in total

1.  High fibrosis-4 index predicts the new onset of ischaemic heart disease during a 10-year period in a general population.

Authors:  Yukimura Higashiura; Marenao Tanaka; Kazuma Mori; Takuma Mikami; Itaru Hosaka; Hirofumi Ohnishi; Nagisa Hanawa; Masato Furuhashi
Journal:  Eur Heart J Open       Date:  2022-04-16

Review 2.  The ABCC6 Transporter: A New Player in Biomineralization.

Authors:  Guillaume Favre; Audrey Laurain; Tamas Aranyi; Flora Szeri; Krisztina Fulop; Olivier Le Saux; Christophe Duranton; Gilles Kauffenstein; Ludovic Martin; Georges Lefthériotis
Journal:  Int J Mol Sci       Date:  2017-09-11       Impact factor: 5.923

Review 3.  Nonalcoholic fatty liver disease and cardiovascular disease phenotypes.

Authors:  Giandomenico Bisaccia; Fabrizio Ricci; Cesare Mantini; Claudio Tana; Gian Luca Romani; Cosima Schiavone; Sabina Gallina
Journal:  SAGE Open Med       Date:  2020-06-20

4.  Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia.

Authors:  Giuseppe Mandraffino; Carmela Morace; Maria Stella Franzè; Veronica Nassisi; Davide Sinicropi; Maria Cinquegrani; Carlo Saitta; Riccardo Scoglio; Sebastiano Marino; Alessandra Belvedere; Valentina Cairo; Alberto Lo Gullo; Michele Scuruchi; Giovanni Raimondo; Giovanni Squadrito
Journal:  Biomedicines       Date:  2022-07-22

5.  Arterial Calcifications in Patients with Liver Cirrhosis Are Linked to Hepatic Deficiency of Pyrophosphate Production Restored by Liver Transplantation.

Authors:  Audrey Laurain; Isabelle Rubera; Micheline Razzouk-Cadet; Stéphanie Bonnafous; Miguel Albuquerque; Valérie Paradis; Stéphanie Patouraux; Christophe Duranton; Olivier Lesaux; Georges Lefthériotis; Albert Tran; Rodolphe Anty; Philippe Gual; Antonio Iannelli; Guillaume Favre
Journal:  Biomedicines       Date:  2022-06-24

6.  Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type 2 diabetes.

Authors:  Ryotaro Bouchi; Yujiro Nakano; Norihiko Ohara; Takato Takeuchi; Masanori Murakami; Masahiro Asakawa; Yuriko Sasahara; Mitsuyuki Numasawa; Isao Minami; Hajime Izumiyama; Koshi Hashimoto; Takanobu Yoshimoto; Yoshihiro Ogawa
Journal:  Cardiovasc Diabetol       Date:  2016-04-14       Impact factor: 9.951

Review 7.  Relationship between non-alcoholic fatty liver disease and coronary heart disease.

Authors:  Ugur Arslan; Mustafa Yenerçağ
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

8.  Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease.

Authors:  Jiwoo Lee; Hwi Seung Kim; Yun Kyung Cho; Eun Hee Kim; Min Jung Lee; In Yong Bae; Chang Hee Jung; Joong-Yeol Park; Hong-Kyu Kim; Woo Je Lee
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.